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Zusammenfassung
Hintergrund: Niedrig dosiertes Capecitabin in Kombi-
nation mit hoch dosiertem Celecoxib wurde als metro-
nomische, antiangiogene Therapie bei fortgeschrittenen
Tumorpatienten im Rahmen einer Phase-II-Studie einge-
setzt. Das Monitoring antiangiogener Effekte umfasste
Untersuchungen mittels dynamischer-kontrastmittel-
verstärkter (DCE)-MRI. Material und Methoden: 37 Pa-
tienten (21 Männer, 16 Frauen) mit einem mittleren Alter
von 60 Jahren und progressivem Tumorwachstum wur-
den behandelt. Die Patienten wurden mit 2 × 500 mg Ca-
pecitabin und 2 × 400 mg Celecoxib po/Tag kontinuierlich
bis zum Nachweis einer Tumorprogression behandelt.
Für das Monitoring antiangiogener Effekte wurde die
DCE-MRI-Untersuchungstechnik angewandt. Das Tumor-
ansprechen wurde entsprechend RECIST-Kriterien aus-
gewertet, die Nebenwirkungen nach dem CTC-Katalog
Version 2,0. Ergebnisse: Die Therapie wurde gut toleriert
ohne schwerwiegende Toxizitäten Grad 3 und 4. Die mitt-
lere Zyklusanzahl betrug 4 (von 1–15+). Krankheitsstabili-
sierung nach 3 Monaten trat bei 11 Patienten auf. Bei 
6 Patienten wurden lang anhaltende stabile Krankheits-
phasen induziert mit einer mittleren Anzahl von 10 Zy-
klen (7–15+). Die DCE-MRI-Untersuchung zeigte eine Re-
duktion der Tumorgefäßpermeabilität und des Blutflus-
ses bei den Patienten, die eine stabile Krankheitsphase
erreichten. Schlussfolgerung: Die Kombination Capecita-
bin und Celecoxib ist gut verträglich, antiangiogen und
zeigte antitumorale Effekte. Patienten mit einer schnellen
Progression bei Aufnahme in die Studie profitierten
nicht.
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Summary
Background: Combined therapy of continuous low dose
capecitabine and high dose celecoxib targeting angio-
genesis was used in a phase II trial to treat advanced
cancer patients. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) was used to monitor an-
tiangiogenic effects. Material and Methods: 37 Patients
(21 men, 16 women), mean age 60 years, with advanced
and progressive cancer of various tumor types were in-
cluded. Therapy consisted of 2 × 500 mg oral capecita-
bine/day and 2 × 400 mg oral celecoxib/day continuously
until progression of disease. To monitor antiangiogenic
effects, DCE-MRI measurements were performed at
baseline, after 1 month, and after 3 months of therapy.
Tumor assessment was performed according to RECIST
criteria, toxicity was evaluated according to the CTC ver-
sion 2.0 catalogue. Results: Therapy was well tolerated
without grade 3 and 4 toxicities. The mean number of
treatment cycles was 4 (range: 1–15+). Disease stabiliza-
tion after 3 cycles was seen in 11 patients. 6 patients
were stable over long periods. The mean number of
treatment cycles in this group was 10 (range: 7–15+).
DCE-MRI demonstrated a reduction of tumor vessel per-
meability and blood flow in patients who reached stable
disease or some minor regression. Conclusion: Continu-
ous dosing of the combination of capecitabine and ce-
lecoxib was well tolerated, produced antiangiogenic ef-
fects, and has antitumor activity. Patients with rapid pro-
gression did not benefit.
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Introduction
Cytotoxic drugs affect proliferating cancer cells as well as nor-
mal cells such as bone marrow, intestinal mucosa, or hair folli-
cle cells. Effects include damage to the cells of the tumor
microenvironment, in particular the epithelial cells (ECs) of
the growing tumor vasculature. In comparison to myocytes,
fibroblasts and tumor cells (TCs), ECs are highly vulnerable
to very low anthracycline concentrations [1]. Cytotoxic drugs
usually are administered at doses close to the maximum toler-
ated dose (MTD), targeting the malignant TC. MTD-based
chemotherapy needs longer intervals between treatment cy-
cles to allow recovery of healthy tissues. Alternatively, it has
been proposed to use conventional cytotoxic chemotherapeu-
tics to target tumor angiogenesis [2]. This approach is not in-
validated by the fact that a monoclonal antibody as well as
tyrosine kinase inhibitors interfering with the vascular endo-
thelial growth factor (VEGF)-VEGF receptor system are cur-
rently available [3].
The basics of tumor neo-angiogenesis and tumor growth [4]
have been established, and there is growing evidence that old
cytotoxic drugs can be used to target the tumor vasculature
via ECs. Only a few clinical trials with metronomic (i.e. daily
dosing) schedules have been published, all of them were
phase II or pilot studies. In 1999, several publications showed
in model systems that the camptothecins topotecan [5] and
irinotecan [6] as well as vinblastin [7] and a purine analogue
[8] featured antiangiogenic properties when used at very low
concentrations. In 2000, a combination of metronomic chemo-
therapy with a targeted antiangiogenic drug resulted in a re-
markably prolonged survival of mice bearing neuroblastomas
[9]. In 2006, a clinical study using a combined biodifferentiat-
ing and antiangiogenic oral metronomic therapy in children
with relapsed solid tumors showed feasibility and efficacy.
These results underline the potential of metronomic anti-
cancer therapies [10, 11]. Continuous chemotherapy adminis-
tration is daily practice in several chemotherapy combinations
(e.g. epidoxorubicin, cisplatin, 5-fluorouracil (5-FU)) but gen-
erally with dosages near the MTD to target the TC itself.
These schedules contrast with the characteristics of a metro-
nomic low-dose antiangiogenic therapy concept. The value of
such low dose cytotoxic concepts using antiangiogenic daily
schedules to target the EC remains to be fully assessed. 
Besides the classical cytostatic drugs, there are several other
approved drugs with antiangiogenic properties. Rapamycin is
a bacterial macrolide that forms a complex with the FK-bind-
ing protein (FKBP-12) that binds with high affinity to the
mammalian target of rapamycin (mTOR). Rapamycin in-
hibits primary and metastatic tumor growth by interfering
with angiogenesis and the vascular endothelial growth factor
[12, 13]. Peroxisome proliferator activator receptors (PPAR)
are members of a superfamily of nuclear hormone receptors.
Drugs that inhibit this receptor (PPARγ agonists) which have
been approved for the treatment of diabetes mellitus also ex-
hibit antiangiogenic effects. PPARγ is highly expressed in the
tumor endothelium, and interfering drugs like rosiglitazone,
troglitazone, and pioglitazone result in inhibition of TC
growth [14, 15]. In addition, the statins are interesting, be-
cause, for these drugs, antitumor properties have been de-
scribed such as induction of growth arrest and apoptosis, in-
hibition of metastasis, and inhibition of angiogenesis [16].
Experimental studies have shown that cyclooxygenase-2
(COX-2) is involved in tumor development and progression.
Selective inhibitors of COX-2, the coxibs, block tumor growth
by different mechanisms, displaying antiangiogenic and
proapoptotic effects [17–19]. Surprisingly, not all anticancer
effects of selective COX-2 inhibitors are COX-2 dependent,
but some are COX-2-independent [20]. A pivotal study
demonstrated that celecoxib suppresses adenomatous polyps
and causes regression of existing polyps in patients with famil-
ial adenomatous polyposis [21]. In 1999, the FDA approved
celecoxib as a preventive therapy at a suggested dose of 400
mg twice daily. Combinations of COX-2 inhibitors with classi-
cal cytotoxics showed promising results suggesting additional
or synergistic anticancer effects in non-small cell lung cancer
and colorectal cancer [22, 23]. Metronomic schedules with
cytotoxic drugs have limitations since not all drugs are avail-
able for oral application. Cytotoxic drugs that may be taken
orally were tested with respect to their inhibitory effects on
ECs and TCs.
All tested drugs were more active against the ECs in compari-
son to TCs, with much lower inhibitory concentrations (IC50)
for ECs ( 4.03 × 10–6–6.16 × 10–14 M) than TCs (7.44 ×10–2–1.9
× 10–11 M). In general, ECs were found to be 5–100 times
more sensitive than TCs as shown for methotrexate, vin-
blastin, cyclophosphamide, paclitaxel, docetaxel, 5-FU, dox-
orubicin, idarubicin, and vepesid [24, 26, 27]. 
Thymidine phosphorylase (TP) is induced in the tumor mi-
croenvironment in stromal cells. Angiogenesis is promoted
and apoptosis is inhibited by TP which may explain why tu-
mors that overexpress TP have an unfavorable prognosis [26].
TP is also present in proliferating ECs which are important
for the vascularization of tumors [28]. Capecitabine is an oral
fluoropyrimidine carbamate, designed to generate 5-FU pref-
erentially in cells with a high expression of TP [29]. Thus,
these findings provided the rationale for investigating the
combination of capecitabin and celecoxib in a phase II clinical
study in patients with advanced tumors of different origin.
Antiangiogenic effects were monitored by dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) tech-
nique, which is currently the most reliable method for this
purpose [30].
Material and Methods
Patient Selection
Patients older than 18 years with a histological or cytological diagnosis
of locally advanced or metastatic tumor were eligible. All patients had
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to have confirmed progressive disease (PD) after 1 (or more if avail-
able) standard palliative therapy. All patients were required to have
recovered from any prior chemotherapy, radiotherapy, or surgery pro-
cedure before study entry. The presence of measurable disease, ade-
quate hematologic, cardiovascular, renal, and hepatic function was
mandatory. Patients with unstable cardiovascular disease, active infec-
tion, active gastric/duodenal ulcer, necessary treatment with non-
steroidal anti-inflammatory drugs, corticoids, fluconazole, lithium, or
oral anticoagulation were considered ineligible. The protocol was re-
viewed and approved by the institutional ethical committee, and in-
formed consent was obtained from all patients. 
Study Evaluation and Treatment
Baseline evaluation included clinical examination, biochemical and
hematological tests, chest X-ray, ultrasound, and MRI examination in-
cluding a DCE-MRI scan. A region-of-interest (ROI)-based analysis was
performed on the DCE-MRI data with pharmacodynamic modeling ap-
plying the Tofts model. The region of interest was mainly a metastatic
lesion but could also be the primary tumor, depending on the best as-
sumption for a reliable measurement baseline and for follow-up. The re-
sulting parameter is the transfer constant Ktrans related to blood flow and
permeability. CT scans were only performed if ultrasound and MRI ex-
aminations were not possible and lung metastasis were not evaluable with
conventional X-ray. Complete blood counts including differentiation
were then repeated every 2 weeks, and biochemical tests were done every
4 weeks. 1 treatment cycle was defined as a 4-week treatment. The DCE-
MRI procedure was repeated after 1 cycle. The first regular clinical stag-
ing was performed after 3 cycles with all methods necessary for response
evaluation including the MRI and DCE-MRI. Thereafter, tumor staging
was performed after every 3rd cycle, in the case of clinical signs of pro-
gression earlier. Treatment was administered as follows: celecoxib 400 mg
twice daily continuously and capecitabine 500 mg twice daily continu-
ously. The drugs were given in the morning and 12 h later.
Biometric Analysis
The primary endpoint was stable disease (SD) after 3 treatment cycles.
Secondary endpoints were the documentation of antiangiogenic effects
measured by DCE-MRI, time to progression (TTP), overall survival (OS)
and the evaluation of drug-induced toxicity. TTP and OS curves were
calculated according to the use of Kaplan-Meier method using standard
software.
Results
37 patients were enrolled, 21 male, 16 female. Median age was
60 years, range 32–78. 12 patients had metastatic colorectal
cancer, 10 advanced renal cell carcinoma, 2 gallbladder can-
cer, 2 cholangiocellular cancer, 3 pancreatic cancer, and 8 var-
ious other tumors. The patient characteristics are depicted in
table 1. All patients had confirmed PD at the time of inclu-
sion. 35 patients completed at least 1 treatment cycle. 2 pa-
tients dropped out during the first 4 weeks because of rapid
PD, therapy was stopped and best supportive care was provid-
ed. All patients were evaluable for toxicity. Hematological
toxicity was negligible: 15 patients grade 2, 2 patients grade 3
anemia; no episodes of leukopenia or thrombocytopenia 
> grade 1 were observed. No treatment interruptions or dose
reductions were necessary. 1 cardiovascular event with atrial
fibrillation and 1 bleeding episode with hemoptysis were doc-
umented, both grade 1. Hematological and non-hemato-
logical toxicities (according to CTC catalogue version 2.0) are
summarized in table 2.
20 of 37 patients reached the first regular tumor evaluation
point after 3 cycles of treatment. 17 (46%) patients dropped
out due to PD within the first 3 cycles. 9 patients had tumor
progression after the 3rd cycle. Thus, in summary, 26 of 37 had
PD within 3 months. 11 patients were treated for more than 
3 cycles (4 × renal cell cancer, 5 × gastrointestinal cancer, 
1 non-small cell lung cancer, and 1 cancer of unknown pri-
Characteristics Patients, n
Median age, years (range) 60 (32–78)
Eligible patients
Male 19
Female 16 
Disease status
Locally advanced 0
Metastatic 35 
Tumor types
Colorectal cancer 12 
Renal cell cancer 10 
Gallbladder cancer 2 
Cholangiocellular carcinoma 2 
Pancreatic cancer 3 
Other solid tumors 8 
ECOG performance status  
0 11 
1 20 
2 4 
Palliative cytotoxic pretreatments, n
0 3 
1 7 
2 8 
3 6 
4 5 
5 4 
7 2
Table 1. Patient
characteristic
Table 2. Hematological and non-hematological toxicity (National Can-
cer Institute Common Toxicity Criteria, version 2.0)
Toxicity Patients, n

Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 0 1 0 0
Thrombocytopenia 3 0 0 0
Anemia 8 15 2 0
Aspartat aminotransferase 5 6 2 0
Alanine aminotransferase 12 2 1 0
Nausea/vomiting 14 3 0 1
Dyspepsia/dysphagia 5 2 0 0
Hand-foot syndrome 3 1 0 0
Dry skin 2 1 0 0
Conjunctivitis 5 0 0 0
Cardiovascular events 1 0 0 0
Bleeding 1 0 0 0
Fatigue 10 1 1 0
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
2:
07
:4
9 
PM
632 Onkologie 2007;30:629–635 Steinbild/Arends/Medinger/Häring/Frost/
Drevs/Unger/Strecker/Hennig/Mross
mary). Of those patients, 6 had 5-FU in the treatments before,
and 5 patients never got this drug. All of these 11 patients had
PD within 1 year of treatment, except for 1 patient with renal
cell cancer who was 32 months on treatment before he pro-
gressed. The response to treatment using the RECIST criteria
and TTP are summarized in table 3. The OS and TTP curves
of the whole patient group are shown in figure 1.
34 patients were included in the final DCE-MRI data analysis.
1 patient with SD was excluded from the analysis since no
contrast agent uptake could be observed in the target lesion.
The Ktrans time profiles do not reveal a clear picture of a dif-
ference in response to therapy for the patients with either PD
or SD. A reduction of more than 40% (which is considered as
significant) in Ktrans was seen in individual patients at the end
of cycle 3. These patients had SD. An example of a pixelwise
generated Ktrans map for a patient with SD at the end of cycle
3 is represented in figure 2. A significant reduction in Ktrans,
particularly in the tumor rim, is observed at the end of cycle 3.
The mean percentage change of Ktrans from baseline is pre-
sented in figure 3 for the patients with PD and SD at the end
of cycle 1 and cycle 3. Error bars mark the 90% confidence
interval of the mean value. Patients with PD show an average
increase of 41.8% in Ktrans at the end of cycle 1, whereas pa-
tients with SD show a reduction of 14.7%. A mean reduction
of 16.2% is observed in the patients (n = 5) with PD at the end
of cycle 3, and of 34.2% in the patients with SD indicating an
antiangiogenic response to metronomic therapy. A minor re-
duction of 16% of Ktrans is not sufficient to slow down tumor
growth. SD was only observed with greater changes of Ktrans. 
Discussion
In general, the tolerability of the drug combination cape-
citabin and celecoxib was good. No drug-related serious
adverse effects (SAE) were observed. Hospitalization due to
medical reasons other than study drug-related were the most
frequent reason for SAE reports. No serious cardiac problems
were observed. Most of the patients felt comfortable with the
used drug dosages possibly also due to the anti-inflammatory
and anti-analgetic effects of celecoxib. Nearly 30% of all pa-
tients had stabilization of tumor growth after 12 weeks. These
were patients with renal cell cancer and cancer from the gas-
Response Patients, n (%)
Evaluable patients 35/37 (95)
Non-evaluable patients 2/37 (5)
Stable disease 11/35 (34)
Progressive disease 24/35 (66)
Mean TTP, weeks (range) 15 (2–56)
TTP = Time to progression.
Table 3. Response
to treatment and TTP
Fig. 3. Mean per-
centage change of
Ktrans for patients
with progressive dis-
ease (PD) and stable
disease (SD) at the
end of cycles 1 and 3.
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Fig. 1. Overall survival of all patients and time on study (solid line =
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Fig. 2. Ktrans and iAUC60 maps of patient 12. A significant reduction in
Ktrans , particularly in the tumor rim, is observed at the end of cycle 3.
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trointestinal tract. However, the majority of patients had no
clinical benefit because tumor growth was too fast. We did not
see any remissions which can be explained by the fact that
pre-existing vessels may not be affected by the metronomic
therapy. Thus, tumor growth can only be inhibited in the
region with new vessels but not in the region of pre-existing
vessels, so a significant tumor reduction can not be expected.
These results indicate that for rapid tumor growth intermit-
tent MTD-based cytotoxic therapy is necessary. The combina-
tion of metronomic and intermittent chemotherapy, as sug-
gested [31] and successfully used in animal models [32], would
be a merger of both types of anticancer treatment and should
be considered for phase I and II evaluations. DCE-MRI al-
lows tracking of changes in the tumor perfusion and the vessel
permeability induced by antiangiogenic therapy. The DCE-
MRI results, expressed as Ktrans or iAUC60 reduction in com-
parison to baseline as a surrogate for blood flow and vessel
permeability [33], have shown that this metronomic therapy is
indeed able to reduce these 2 parameters indicating that the
concept is valid. Patients with early progression after 1 treat-
ment cycle showed an increase in Ktrans. Interestingly, patients
who had received 3 cycles of therapy and had PD according to
the RECIST criteria showed a small reduction of Ktrans which
was less than the mean in the group with SD. This points to an
effect of the therapy in these patients on blood flow and ves-
sel permeability, which is, however, not strong enough to slow
down or induce a stop of tumor growth. Cumulative experi-
ence from > 1,000 DCE-MRI measurements in the past 7
years indicates that only a significant decrease in Ktrans (40%
or more) is able to slow down or stop further tumor growth.
Use of the same DCE-MRI technology in clinical trials with
specific tyrosine kinase inhibitors of the VEGF-receptor
system resulted in higher reductions of the Ktrans and iAUC60
in those patients judged as ‘responder’ [30, 34, 35].
Many new agents have been developed to inhibit specific
pathways of angiogenesis, and some of these drugs such as be-
vacizumab, sunitinib, and sorafenib are now approved. Alter-
natively, inhibition of angiogenesis may be achieved with
some approved ‘old’ drugs as well [25, 36–38]. Metronomic
dosing means that continuously small amounts of the drug are
present in the central compartment, acting at sites where ac-
tion is useful for stopping tumor growth. A major target of an
antiangiogenic therapy are the proliferating ECs of tumor
vessels. Many of the cytotoxic drugs in use are given intra-
venously with a rapid fade from the central compartment, but
there is a remarkable list of drugs which are available for
metronomic schedules where the drugs are given orally over
long periods of time at a much lower dose compared to inter-
mittent intravenous application. These drugs are: treosulfan,
trofosfamide, cyclofosfamide, vepesid, capecitabine, thiotepa,
temozolamid, methotrexate, idarubicin, and topotecan. Not
all of these drugs are available in such low dosages that a dai-
ly continuous administration is possible. A metronomic
schedule of a cyctotoxic drug should guarantee sufficient drug
concentrations at each moment for the inhibition of the target
cells which are the proliferating ECs of the tumor vessels.
Capecitabine is approved for a schedule with 2 × 1,250 mg/m2/
day for 14 days with 7 days off which is approximately 
4,500 mg/day. From clinical experience it is known that a sig-
nificant number of patients develop a severe hand-foot syn-
drome, and therefore a rest period has to be offered to reach
full recovery. Additionally, a dose reduction has to be consid-
ered when therapy is restarted to avoid this type of toxicity.
Clinical experience in our department in the past has shown
that the dose of capecitabine had to be reduced in some pa-
tients to very low amounts (1/5 of the full dose) without com-
promising the antitumor effect. This clinical observation as
well as the laboratory data that have shown that the sensi-
tivity of proliferating ECs to cytostatic agents is much higher
than the sensitivity of TCs (5–100-fold) led to the develop-
ment of the treatment protocol using capecitabine at a fixed
continuously low daily dose (2 × 500 mg which is nearly 1/5 of
the normal dose) together with celecoxib at a daily dose of 
2 × 400 mg, a drug with antiangiogenic properties [18]. The
proliferating ECs are the first to be reached when the drugs
under study enter the central compartment. Because TP – the
activating enzyme necessary for the generation of 5-FU – is
still present in the proliferating ECs, significant amounts of 
5-FU can act in the ECs thereby stopping proliferation in this
cell population. Whether this low drug amount is also able to
inhibit proliferating TCs, is unknown and cannot be ruled out.
The reason for combining a COX-2 inhibitor such as celecox-
ib with the above-mentioned therapy is based on preclinical
data showing that COX-2 mediates the production of prosta-
glandin E2 in epithelial tissues, resulting in an activation of
signaling pathways that promote cell proliferation and inhibit
cell death [39]. However, the influence of a metronomic ther-
apy on tumor growth is probably much smaller than a cytosta-
tic MTD-driven antitumor therapy. Ongoing tumor growth is
still possible because the non-proliferating ECs of still exist-
ing vessels are unaffected but further tumor growth should be
slowed down until a new balance is reached. Nevertheless,
there is enough time and space to improve the results of
metronomic schedules because the truly new antiangiogenic
drugs are still under development. Optimization of metro-
nomic therapies featuring antiangiogenic properties is possi-
ble with other combinations of cytotoxic and non-cytotoxic
drugs (with angiogenic effects) including rapamycin [12], pi-
oglitazone [15], cyclooxygenase-2 [17], arsenic [40], cannabi-
noids [41]), and zoledronic acid [42], all described as having
antiangiogenic properties too. Even the combination of multi-
targeted signal transduction inhibitors (some are already ap-
proved), metronomic low-dose as well as MTD-driven cyto-
toxic regimens are in discussion [36]. Several metronomic
studies have been published. In a series of combinations of pi-
oglitazone, rofecoxib, and trofosfamide in melanoma/sarcoma
[43], malignant vascular tumors [44], and kaposi sarcoma [45],
tumor regressions and stabilization have been described. In a
Onkologie 2007;30:629–635Metronomic Anticancer Therapy 633
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series of studies, celecoxib was combined with infusional 5-FU
in advanced pancreatic cancer [46] and other tumors [25].
Low-dose metronomic methotrexate and cyclophosphamide
were evaluated in breast cancer with encouraging results [47].
Rofecoxib and low-dose treosulfan were tested in a pilot
study in melanoma patients [48], and metronomic low-dose
cyclophosphamide in combination with dexamethasone was
used in a trial with prostate cancer patients [49]. In a phase I
trial, the combination of celecoxib with erlotinib was assessed
in patients with non-small cell lung cancer, also with encour-
aging results [50].
The main criticism with respect to all published studies is still
the low patient number and the use as ‘last’ line treatment in-
stead of best supportive care. In general, the tolerability of
metronomic therapies was reported as very acceptable. Most
importantly, metronomic approaches need to demonstrate
that they are better than best supportive care thus the length
of a SD period and the quality of life reached are important
endpoints of such studies. 
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